Healthcare-associated infections

Hospital Acquired Infection Control Market Analysis Report 2021-2028 by Type (Equipment, Services, Consumables), by End User (Hospitals & ICUs, Ambulatory Surgical & Diagnostic Centers) - ResearchAndMarkets.com

Retrieved on:

Wednesday, August 4, 2021

Infectious Diseases, Hospitals, Health, Health, Medical specialties, Infectious diseases, Epidemiology, Occupational safety and health, Healthcare-associated infections, Hospital-acquired infection, COVID-19, Infection prevention and control, Infection, Surgery

The "Hospital Acquired Infection Control Market Size, Share & Trends Analysis Report by Type (Equipment, Services, Consumables), by End User (Hospitals & ICUs, Ambulatory Surgical & Diagnostic Centers), by Region and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Hospital Acquired Infection Control Market Size, Share & Trends Analysis Report by Type (Equipment, Services, Consumables), by End User (Hospitals & ICUs, Ambulatory Surgical & Diagnostic Centers), by Region and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
The key factors driving the market growth include the rising incidence of Hospital Acquired Infections (HAIs), supportive government initiatives and the COVID-19 pandemic.
The demand for infection control equipment and consumables also stemmed from the need to stop the spread of COVID-19.
The company was merged into Getinge's Infection Control portfolio to expand its offerings in the business area of Surgical Workflows
Chapter 3 Hospital Acquired Infection Control Market Variables, Trends & Scope

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on:

Monday, August 2, 2021

Medical specialties, Microbiology, Infectious diseases, Acid-fast bacilli, Bacterial diseases, Bacteriology, Infectious causes of cancer, Healthcare-associated infections, Nontuberculous mycobacteria, Omadacycline, Mycobacterium, Tuberculosis

These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.

Key Points:

These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.
Paratek has a collaboration agreement withZaiLab for the development and commercialization of omadacycline in the greaterChinaregion and retains all remaining global rights.
Paratek is also conducting a Phase 2b Study in a rare disease, Nontuberculous Mycobacterial (NTM) Pulmonary Disease, caused by Mycobacterium abscessus Complex (MABc) with NUZYRA.
Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

Paratek Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 9, 2021

Retrieved on:

Monday, August 2, 2021

Domestic investors wishing to participate in the call should dial: 855-327-6837 and international investors should dial: 631-891-4304.

Key Points:

Domestic investors wishing to participate in the call should dial: 855-327-6837 and international investors should dial: 631-891-4304.
Paratek Pharmaceuticals, Inc.is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government andmilitary use.
Paratek has a collaboration agreement withZaiLab for the development and commercialization of omadacycline in the greaterChinaregion and retains all remaining global rights.
Paratek is also conducting a Phase 2b Study in a rare disease, Nontuberculous Mycobacterial (NTM) Pulmonary Disease, caused by Mycobacterium abscessus Complex (MABc) with NUZYRA.

Entasis Therapeutics and Zai Lab Complete Patient Enrollment in the ATTACK Phase 3 Registrational Clinical Trial of Sulbactam-Durlobactam

Retrieved on:

Tuesday, July 27, 2021

Health, Articles, Moraxellaceae, Carbapenem, Healthcare-associated infections, Acinetobacter, Antimicrobial resistance, Antibiotic, ESKAPE

WALTHAM, Mass. and SHANGHAI, China and SAN FRANCISCO, July 27, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, and Zai Lab Limited (NASDAQ:ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, announced today that patient enrollment in the ATTACK Phase 3 registrational clinical trial of sulbactam-durlobactam (SUL-DUR) is now complete, with top-line data readout anticipated early in the fourth quarter of 2021.

Key Points:

To our knowledge, ATTACK is the largest antibiotic-resistant, pathogen-specific registrational trial to be conducted globally and the first to focus specifically on carbapenem-resistant Acinetobacter infections.
Harald Reinhart, M.D., Chief Medical Officer for Autoimmune and Infectious Diseases at Zai Lab, stated, Infections caused by carbapenem-resistant Acinetobacter spp.
ATTACK is a Phase 3 registrational trial that will evaluate the safety and efficacy of SUL-DUR in patients with confirmed carbapenem-resistant Acinetobacter infections.
ATTACK is a global Phase 3 registration trial that enrolled patients at clinical sites from 17 countries.

ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity

Retrieved on:

Monday, July 19, 2021

Peptides, Infectious diseases, Health care, Bacterial diseases, Antibiotics, Healthcare-associated infections, Cyclic peptides, Depsipeptides, Daptomycin, Methicillin-resistant Staphylococcus aureus, Vancomycin

The analysis of bone samples demonstrated that CF-296 has potent anti-staphylococcal activity and, when used with daptomycin, is active and well tolerated in MRSA acute osteomyelitis.

Key Points:

The analysis of bone samples demonstrated that CF-296 has potent anti-staphylococcal activity and, when used with daptomycin, is active and well tolerated in MRSA acute osteomyelitis.
Of note, the addition of CF-296 to both daptomycin or vancomycin resulted in significantly enhanced antibacterial activity in the model, relative to the activity of these standard-of-care antibiotics alone.
ContraFect continues to evaluate CF-296 in further preclinical studies and the potential for future clinical development.
CF-296 was developed by ContraFect and the Company is actively pursuing global rights to this investigational development candidate.

Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus

Retrieved on:

Monday, July 12, 2021

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group or Aptorum), a clinical-stage biopharmaceutical company, announces further positive results of its ongoing Phase 1 clinical trial for ALS-4 (a first in-class anti-virulence approach based small molecule targeting Staphylococcus aureus, including, but not limited to Methicillin Resistant Staphylococcus Aureus (MRSA)).

Key Points:

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group or Aptorum), a clinical-stage biopharmaceutical company, announces further positive results of its ongoing Phase 1 clinical trial for ALS-4 (a first in-class anti-virulence approach based small molecule targeting Staphylococcus aureus, including, but not limited to Methicillin Resistant Staphylococcus Aureus (MRSA)).
In addition, no clinically relevant changes in respect of vital signs, electrocardiogram (ECG), clinical laboratory test results and physical examinations were observed compared to baselines.
Our SAD is still ongoing to gain additional insights as to the effect of food on bioavailability as well as pharmacokinetics.
This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

GeoVax Announces Issuance of Hepatitis B Vaccine Patent

Retrieved on:

Wednesday, July 7, 2021

Medical specialties, Health, Clinical medicine, Infectious causes of cancer, Healthcare-associated infections, Viral diseases, Epidemiology, Virus, Zoonoses, Hepatitis, Patent application, Viral hepatitis

11,052,148, entitled Composition and Methods of Generating an Immune Response to Hepatitis B Virus.

Key Points:

11,052,148, entitled Composition and Methods of Generating an Immune Response to Hepatitis B Virus.
The abstract contained in the Companys patent application describes the invention as follows: The compositions and methods are described for generating an immune response to a hepatitis B virus.
The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat an infection caused by hepatitis B virus.
We are pleased now to have been notified of the formal patent issuance.

Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens

Retrieved on:

Thursday, July 1, 2021

Bacteria, Medical specialties, Gram-negative bacteria, Pathogenic bacteria, Moraxellaceae, Infectious diseases, Healthcare-associated infections, Acinetobacter baumannii, Neisseria, Antibiotic, Acinetobacter

ETX0462 potentially represents the first new antibiotic class in 35 years to treat MDR Gram-negative and biothreat infections.

Key Points:

ETX0462 potentially represents the first new antibiotic class in 35 years to treat MDR Gram-negative and biothreat infections.
Similar in vivo efficacy was also demonstrated for the biothreat pathogens Y. pestis and B. pseudomallei.
Entasis demonstrated that ETX0462 was well tolerated in a rat 14-day GLP toxicology study reaching the limit dose of 2,000 mg/kg.
Entasis pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacterales infections) and ETX0462 (targeting Pseudomonas infections).

Worldwide Healthcare-Acquired Infection Industry to 2026 - Focus on Disinfectants and Sterilization Systems - ResearchAndMarkets.com

Retrieved on:

Wednesday, June 30, 2021

Health, General Health, Health, Medical specialties, Biocides, Hygiene, Infectious diseases, Healthcare-associated infections, Electron beam, Sterilization, Hospital-acquired infection, Antimicrobial, Disinfectant, Trend

Analyses of the global market trends, with data from 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026

Key Points:

Analyses of the global market trends, with data from 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
Market outlook and forecast trends of pharmaceutical treatment (antimicrobials and vaccines), environment treatment (disinfectants, sterilization systems etc.)
and provisions in medical devices (catheters, patient ventilation devices, sterile intravenous [IV] filters) that prevent the occurrence of nosocomial infections
Estimation of the market size and revenue forecasts for HCAI-control market, and corresponding market share analysis by key market segments - technology type, application, and geography
Discussion of the key market dynamics, industry structure, regulatory approval, market deterrents, unmet needs and other factors driving opportunities in microbiology research

OpGen Announces Prospective Clinical Data from Unyvero LRT BAL and Acuitas AMR Gene Panel for Isolates Data Presented at World Microbe Forum

Retrieved on:

Wednesday, June 30, 2021

Medical specialties, Infectious diseases, Microbiology, Bacterial diseases, Healthcare-associated infections, Bacteriology, Gram-positive bacteria, Pathogenic bacteria, Staphylococcus aureus, Infection

Changes in therapy occurred significantly faster with the Unyvero LRT BAL, on average 21 hours faster, compared to when conventional AST result was available.

Key Points:

Changes in therapy occurred significantly faster with the Unyvero LRT BAL, on average 21 hours faster, compared to when conventional AST result was available.
Based on real-time clinical use of the Unyvero LRT BAL panel, they determined that the panels S. aureus NPV is 97%, giving a solid indication that MRSA is not present causing the respiratory infection.
The Unyvero LRT BAL panel includes rapid and reliable detection of Pneumocystis jirovecii in just 5 hours with only about 2 minutes of hands-on time.
This press release includes statements regarding the results of studies conducted by independent infectious disease professionals presented at a recent webinar and at the 2021 World Microbe Forum on OpGens Unyvero LRT BAL panel as well as the Acuitas AMR Gene Panel for Isolates (RUO) and their potential clinical benefits.